In December 2006, CIP IV formed a €193m joint venture with ABN AMRO Capital. Forbion Capital Partners span out of the bank to manage the portfolio of 26 life science companies.
In January 2006, CIP IV invested in ICICI Venture’s India Advantage Fund I – India’s first secondaries transaction. Coller’s proposals were tailored to meet the needs of individual sellers.
In September 2004, CIP IV acquired a $90 million portfolio of companies from Dresdner Kleinwort Benson.
In January 2004, CIP IV closed another landmark secondaries investment – the acquisition of a $900 million portfolio from Abbey bank (now part of Banco Santander). The deal involved 41 fund positions, 32 different managers, 16 direct investments, and around 850 underlying companies. The transaction was, at the time, the largest secondaries investment by a single firm.
In December 2001, CIP IV acquired the majority (and subsequently all) of Lucent’s corporate venture portfolio. The assets consisted of 27 companies based on technologies developed at the well-known Bell Labs in the late 1980s and the early 1990s.
In June 2000, CIP III led the acquisition of NatWest’s large private equity portfolio. The NatWest deal was notable for its unprecedented size and complexity – with a value in excess of $1 billion, it was the largest secondaries transaction of its time.